- Home
- ALGS vs KYNB Comparison
ALGS vs KYNB Comparison
Compare ALGS & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | KYNB |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 32.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALGS | KYNB |
|---|---|---|
| Price | $5.58 | $6.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $52.38 | $39.67 |
| AVG Volume (30 Days) | ★ 39.1K | 23.8K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.30 | ★ 9552.08 |
| EPS | N/A | ★ N/A |
| Revenue | $2,186,000.00 | ★ $6,440,000.00 |
| Revenue This Year | $1,562.10 | $4.23 |
| Revenue Next Year | N/A | $14.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.98 | $6.32 |
| 52 Week High | $13.69 | $9.58 |
Technical Indicators
Market Signals| Indicator | ALGS | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 32.48 |
| Support Level | $4.81 | $6.61 |
| Resistance Level | $6.12 | $7.41 |
| Average True Range (ATR) | 0.38 | 0.33 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 58.78 | 6.16 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.